Insider Transactions in Q3 2021 at Cullinan Oncology, Inc. (CGEM)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
1,713
-0.02%
|
$49,677
$29.09 P/Share
|
|
Aug 25
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
237
-0.09%
|
$6,873
$29.09 P/Share
|
|
Aug 25
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,713
-0.02%
|
$49,677
$29.09 P/Share
|
|
Aug 24
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
50,882
-0.65%
|
$1,475,578
$29.48 P/Share
|
|
Aug 24
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
7,025
-2.57%
|
$203,725
$29.48 P/Share
|
|
Aug 24
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,822
-0.65%
|
$1,473,838
$29.48 P/Share
|
|
Aug 23
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
53,359
-0.67%
|
$1,547,411
$29.11 P/Share
|
|
Aug 23
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
7,376
-2.63%
|
$213,904
$29.11 P/Share
|
|
Aug 23
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
53,359
-0.67%
|
$1,547,411
$29.11 P/Share
|
|
Aug 23
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
28,118
-23.12%
|
$815,422
$29.0 P/Share
|
|
Aug 18
2021
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.68%
|
$108,000
$27.79 P/Share
|
|
Aug 18
2021
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+12.94%
|
$16,000
$4.3 P/Share
|
|
Aug 11
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
2,510
-0.03%
|
$72,790
$29.05 P/Share
|
|
Aug 11
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
347
-0.12%
|
$10,063
$29.05 P/Share
|
|
Aug 11
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,510
-0.03%
|
$72,790
$29.05 P/Share
|
|
Aug 10
2021
|
Patrick Baeuerle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,000
-100.0%
|
$297,000
$27.0 P/Share
|
|
Aug 10
2021
|
Patrick Baeuerle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+50.0%
|
$44,000
$4.3 P/Share
|
|
Aug 10
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
6,914
-1.82%
|
$186,678
$27.44 P/Share
|
|
Aug 09
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
21,204
-7.16%
|
$551,304
$26.82 P/Share
|